A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.
Genitourinary Cancer Targets
Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.
Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.
The FDA has granted accelerated approval to atezolizumab (Tecentriq) for the treatment of locally advanced or metastatic urothelial carcinoma—the most common type of bladder cancer.
Clinicians now have a new targeted therapy option for treating patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy.
The anti-PD-L1 antibody atezolizumab showed significantly improved objective response rates compared to historic controls in a phase II study of patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.
Comprehensive genomic profiling of patients with advanced urothelial carcinoma has revealed a very high frequency of clinically relevant genomic alterations.
A phase II trial found that use of a personalized peptide vaccination improved overall survival in patients with chemotherapy-resistant advanced urothelial bladder cancer.
The targeted therapy, nivolumab (Opdivo, Bristol Myers Squibb), improved median overall survival by 5.4 months among patients with previously treated renal cell carcinoma (RCC) compared to standard of care everolimus (Afinitor).
Researchers have developed a blood test that can identify mutations in the androgen receptor gene that drive resistance to abiraterone. The test could identify prostate cancer patients who will not respond to the treatment.